Advanced Cancer
Conditions
Brief summary
The aim of the study is to assess: * Part A: the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of AsiDNA in patients with advanced solid tumors. * Part B: the safety and preliminary efficacy of AsiDNA in combination with Carboplatin with or without Paclitaxel in patients with Advanced solid tumors.
Interventions
DRUGAsiDNA
All patients will receive a loading dose of AsiDNA iv infusion (D1, D2, D3) followed by weekly iv administrations. At cycle 1: Part B1: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion. Part B2: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered by a 1 hour IV infusion at D8, D15, D22 or 1 hour after the end of AsiDNA infusion for weekly administrations. At each other cycle: AsiDNA will be administered on a weekly basis. Part B1: Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion. Part B2; Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered on a weekly basis by a 1 hour IV infusion. Patients will continue study treatment until disease progression, unacceptable toxicity or patient's refusal to continue.
Sponsors
Valerio Therapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy of at least 3 months. * Patient with histologically or cytologically documented advanced/metastatic primary or recurrent solid tumors who failed or are not eligible to standard therapy (Part A) and who are candidate to Carboplatin (Part B1) and to Carboplatin and Paclitaxel (Part B2). * Part A: Fresh tumor sample from a biopsy * Part B: A most recent available tumor sample from a biopsy for all patients will be collected for retrospective analysis of 6 genes expression profile for validation of further stratification approach (exploratory purpose). * Prior anticancer therapies (chemotherapy, radiation therapy, hormonal therapy, immunotherapy, biological therapy) are allowed under conditions * At least one measurable lesion according to RECIST 1.1; Patient with no measurable lesion can be enrolled, if the tumor evaluation can be properly documented * Must meet select hematological and biochemical laboratory indices Part B only: * Patient must be eligible to Carboplatin (Part B1) and to Carboplatin + weekly Paclitaxel (Part B2). * Patients must not have received more than 6 prior cycles of platinum-based chemotherapy. Key
Exclusion criteria
* Patient with symptomatic/active central nervous system (CNS) metastases * Other tumor location necessitating an urgent therapeutic intervention * Patient with uncontrolled disease-related metabolic disorder * Patient presenting the following abnormal laboratory values at screening: 1. hematuria \> 1+ on dipstick, 2. proteinuria \> 1+ on dipstick * Patient with uncontrolled congestive heart failure defined as New York Heart Association (NYHA) class III or IV, uncontrolled hypertension, unstable heart disease * Patient with significant ECG abnormalities defined as any cardiac dysrhythmia (\> grade 2) * Patient with significant chronic liver disease or active HBV or HCV infection * Patients with HIV infection or an active infection requiring specific anti-infective therapy * Participation in another clinical trial with any investigational drug within 28 days prior to first study drug administration.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of iv infusions of AsiDNA. | At Cycle 1 (a cycle is 21 days for Part A and 28 days for Part B) for all patients | DLTs will be based on the toxicities observed during the first 3 weeks of study treatment (i.e, cycle 1: from Day 1 to Day 21) for Part A and during the 4 weeks of study treatment (i.e, cycle 1: from Day 1 to Day 28) for Part B. MTD is defined as the dose immediately below the unacceptable dose or defined as the highest tested dose if no DLT observed at this dose. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Collection of new Adverse Events and follow-up of all ongoing Adverse Events assessed | At Cycle 1 (at Day 1; Day 3; Day 8; Day 15) and at Cycle 2 (at Day 1; Day 8; Day 15) and at each subsequent cycles in any (at Day 1; Day 8; Day 15) for all patients | Adverse Events will be reported and graded based on the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events (AE) \[CTCAE\] scale, version 4.03. |
| Elimination half-life (t1/2) of iv infusions of AsiDNA | At Cycle 1 (at Day 1; Day 3; Day 8; Day 15) and at cycle 2 (at Day 1) for all patients | The following standard plasma PK parameter for IV AsiDNA will be analyzed: elimination half-life (t1/2) in hours |
| Peak plasma concentration of iv infusions of AsiDNA | At Cycle 1 (at Day 1; Day 3; Day 8; Day 15) and at cycle 2 (at Day 1) for all patients | The following standard plasma PK parameter for IV AsiDNA will be analyzed: peak plasma concentration (Cmax) in ng/mL |
| ECG evaluation for safety assessment | Before each cycle (e.g at Day 1 of cycle 1; Day 1 of cycle 2 and Day 1 of each subsequent cycles if any) per usual center's practice. | 12-lead ECG will be performed before each cycle (e.g at Day 1 of cycle 1; Day 1 of cycle 2 and Day 1 of each subsequent cycles if any) per usual center's practice. |
| Area under the curve of iv infusions of AsiDNA | At Cycle 1 (at Day 1; Day 3; Day 8; Day 15) and at cycle 2 (at Day 1) for all patients | The following standard plasma PK parameter for IV AsiDNA will be analyzed: area under the curve (AUC) in mg\*h/L. |
| Accumulation factor based on total plasma exposure of iv infusions of AsiDNA | At Cycle 1 (at Day 1) and at cycle 2 (at Day 1) for all patients | The following standard plasma PK parameter for IV AsiDNA will be analyzed: accumulation factor between Day 1 and Day 3 based on total plasma exposure. |
| Time to peak plasma concentration of iv infusions of AsiDNA | At Cycle 1 (at Day 1; Day 3; Day 8; Day 15) and at cycle 2 (at Day 1) for all patients | The following standard plasma PK parameter for IV AsiDNA will be analyzed: time to peak plasma concentration (tmax) in hours |
Countries
Belgium, France
Outcome results
None listed